New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed that ...
Eli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for a new cardiovascular risk reduction claim, as it faces increased competition from Novo Nordisk. The US ...
Ready to start planning your care? Call us at 800-525-2225 to make an appointment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback